The ASA urged Congress to introduce legislation that includes developing an early warning system for disruptions in drug production; requiring manufacturers to have contingency plans for raw materials suppliers; requiring collaboration between the FDA and Drug Enforcement Agency in establishing flexibility for product development and raw material quotas; and establishing incentives for manufacturers.
Related Articles on Anesthesia:
Medicare Updates of Interest to Anesthesiologists and Pain Physicians
Anesthesiologist Survey: Concern Over Blame From Colleagues a Barrier to Reporting Errors
Anesthesiologist Appointed to Medical College of Wisconsin Faculty
